Citi Appointed Depositary Bank For Adaptimmune’s ADR Programme

LONDON--(BUSINESS WIRE)--Citi’s Issuer Services business, acting through Citibank N.A., has been appointed by Adaptimmune Therapeutics plc (“Adaptimmune”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapy products, as the depositary bank for their Nasdaq listed American Depositary Receipt (ADR) programme. Adaptimmune’s ADR programme trades on the Nasdaq Global Select Market under the symbol “ADAP”.

Help employers find you! Check out all the jobs and post your resume.